SCM
BPMC

Sterling Capital Management’s Blueprint Medicines BPMC Stock Holding History

Sterling Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-157
Closed -$20.1K – 3249
2025
Q2 		$20.1K Buy
157
+91
+138% +$9.45K ﹤0.01% 1795
2025
Q1 		$5.84K Buy
66
+1
+2% +$98 ﹤0.01% 2085
2024
Q4 		$5.67K Buy
65
+1
+2% +$92 ﹤0.01% 2412
2024
Q3 		$5.92K Buy
+64
New +$6.36K ﹤0.01% 1696

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Sterling Capital Management's BPMC Position: Q3 2025 in Review

Sterling Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 157 shares — an estimated $20.1K sold.

Sterling Capital Management first reported a position in BPMC in Q3 2024 and held it in 4 quarters. The position peaked at $20.1K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Sterling Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Sterling Capital Management sold 157 Blueprint Medicines shares in Q3 2025, an estimated $20.1K.
  • Sterling Capital Management first reported a position in Blueprint Medicines in Q3 2024 and held it in 4 quarters.
  • Sterling Capital Management's Blueprint Medicines position peaked at $20.1K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Sterling Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.